Bright Light Therapy on Sleep Health in Lung Cancer Patients

NCT ID: NCT07064395

Last Updated: 2025-07-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-09
• Study Completion Date: 2026-02-28

Brief Summary

The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are:

• Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients?
• Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging.

Participants will:

• Receive bright light exposure or usual light exposure every day for 4 weeks
• Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests
• Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks
• Keep a daily sleep log

Conditions

Lung Cancers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

bright light arm

Participants will receive a daily 30-minutes bright light through light visor for 4 weeks.

Group Type: EXPERIMENTAL

bright light

Intervention Type: OTHER

Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.

control arm

Participants will not receive bright light, and keep their usual daily light exposure for 4 weeks.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

bright light

Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• >=18 years of age
• Stage Ib to IIIb primary lung cancer diagnosis
• >=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy
• ECOG performance status is 0 or 1
• Experience problematic sleep (scores of >=8 on the Insomnia Severity Index)
• Able to understand, speak, and read English
• Sighted and mentally competent to consent

Exclusion Criteria

• Pregnant women
• Have metastatic cancer
• on oxygen therapy
• Current diagnosis of seasonal affective disorder or substance abuse
• Engage in shift work or travel across >3 time zones within 2 weeks prior to the study
• Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy
• Take prescribed sedative hypnotics or antipsychotics
• Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)
• Participants with an Insomnia Severity Index <8
• Participants with cognitive impairment (sores of <3 mini-cog test)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Michigan State University

OTHER

Sponsor Role: collaborator

Henry Ford Health System

OTHER

Sponsor Role: lead

Responsible Party

Menghua Tao

Assistant Scientist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Henry Ford Health System

Detroit, Michigan, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Menghua Tao, PhD

Role: CONTACT

mtao1@hfhs.org

313-590-9408

Other Identifiers

F80046

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

17849

Identifier Type: -

Identifier Source: org_study_id